These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1265 related articles for article (PubMed ID: 38473776)

  • 1. Glioblastoma Therapy: Past, Present and Future.
    Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies.
    Shah S
    Med Sci (Basel); 2023 Dec; 12(1):. PubMed ID: 38249077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
    Lefranc F; Rynkowski M; DeWitte O; Kiss R
    Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
    Kardani K; Sanchez Gil J; Rabkin SD
    Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
    Suryawanshi YR; Schulze AJ
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
    Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
    Front Immunol; 2019; 10():2683. PubMed ID: 31798595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of glioblastoma: Recent advances and future prospects.
    Yuan B; Wang G; Tang X; Tong A; Zhou L
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma.
    Strecker MI; Wlotzka K; Strassheimer F; Roller B; Ludmirski G; König S; Röder J; Opitz C; Alekseeva T; Reul J; Sevenich L; Tonn T; Wels WS; Steinbach JP; Buchholz CJ; Burger MC
    Oncoimmunology; 2022; 11(1):2127508. PubMed ID: 36249274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights in the immunobiology of glioblastoma.
    Strepkos D; Markouli M; Klonou A; Piperi C; Papavassiliou AG
    J Mol Med (Berl); 2020 Jan; 98(1):1-10. PubMed ID: 31650201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
    Verdugo E; Puerto I; Medina MÁ
    Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
    Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
    J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sonodynamic therapy and magnetic resonance-guided focused ultrasound: new therapeutic strategy in glioblastoma.
    Bonosi L; Marino S; Benigno UE; Musso S; Buscemi F; Giardina K; Gerardi R; Brunasso L; Costanzo R; Iacopino DG; Maugeri R
    J Neurooncol; 2023 May; 163(1):219-238. PubMed ID: 37179515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma.
    Annovazzi L; Mellai M; Schiffer D
    Cancers (Basel); 2017 May; 9(6):. PubMed ID: 28587121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
    Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
    Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Glioblastoma Therapy: An Update on Current Approaches.
    Angom RS; Nakka NMR; Bhattacharya S
    Brain Sci; 2023 Oct; 13(11):. PubMed ID: 38002496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
    Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.